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Abstract
Background: When designing studies that have a binary outcome as the primary endpoint, the hypothesized
proportion of patients in each population experiencing the endpoint of interest (i.e., π1,π2) plays an important role in
sample size and power calculations. Point estimates for π1 and π2 are often calculated using historical data. However,
the uncertainty in these estimates is rarely addressed.
Methods: This paper presents a hybrid classical and Bayesian procedure that formally integrates prior information on
the distributions of π1 and π2 into the study’s power calculation. Conditional expected power (CEP), which averages
the traditional power curve using the prior distributions of π1 and π2 as the averaging weight conditional on the
presence of a positive treatment effect (i.e., π2 > π1), is used, and the sample size is found that equates the
pre-specified frequentist power (1 − β) and the conditional expected power of the trial.
Results: Notional scenarios are evaluated to compare the probability of achieving a target value of power with a trial
design based on traditional power and a design based on CEP. We show that if there is uncertainty in the study
parameters and a distribution of plausible values for π1 and π2, the performance of the CEP design is more consistent
and robust than traditional designs based on point estimates for the study parameters. Traditional sample size
calculations based on point estimates for the hypothesized study parameters tend to underestimate the required
sample size needed to account for the uncertainty in the parameters. The greatest marginal benefit of the proposed
method is achieved when the uncertainty in the parameters is not large.
Conclusions: Through this procedure, we are able to formally integrate prior information on the uncertainty and
variability of the study parameters into the design of the study while maintaining a frequentist framework for the final
analysis. Solving for the sample size that is necessary to achieve a high level of CEP given the available prior
information helps protect against misspecification of hypothesized treatment effect and provides a substantiated
estimate that forms the basis for discussion about the study’s feasibility during the design phase.
Keywords: Sample size, Clinical trial, Proportions, Binary endpoint, Conditional expected power, Hybrid
classical-Bayesian
Background
When designing a study that has a binary outcome as
the primary endpoint, the hypothesized proportion of
patients in each population experiencing the endpoint of
interest (i.e., π1,π2) plays an important role in sample
size determination. In a two-arm study comparing two
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independent proportions, |π2 − π1| represents the true
hypothesized difference between groups, sometimes also
known as the minimal relevant difference [1]. While the
treatment effect may also be parameterized equivalently
using an odds ratio or relative risk, when appropriate,
the most frequently used sample size formula expresses
the treatment effect using the difference between groups
[2, 3]. In the case of proportions, the variance of the
difference depends on the individual hypothesized val-
ues for the population parameters π1 and π2 under the
alternative hypothesis. Thus, the sample size required to
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detect a particular difference of interest is affected by
both the magnitude of the difference and the individual
hypothesized values.
Traditional sample size formulas incorporate beliefs
about π1 and π2 through single point estimates [1]. How-
ever, there is often uncertainty in these hypothesized
proportions and, thus, a distribution of plausible values
that should be considered when determining sample size.
Misspecification of these hypothesized proportions in the
sample size calculation may lead to an underpowered
study, or one that has a low probability of detecting a
smaller and potentially clinically relevant difference when
such a difference exists [4]. Alternatively, if there is strong
evidence in favor of a large difference, a study may be
overpowered to detect a small hypothesized difference.
Thus, a method for determining sample size that formally
uses prior information on the distribution of study design
parameters can mitigate the risk that the power calcula-
tion will be overly optimistic or overly conservative.
Similar difficulty surrounding the choice of study
parameters for a continuous endpoint with known vari-
ance [5] and for a continuous endpoint with unknown
variance [6] has been discussed previously. We have pre-
sented methods that formally incorporate the distribution
of prior information on both the treatment effect and the
variability of the endpoint into sample size determina-
tion. In this paper, we extend these methods to a binary
endpoint by using a “hybrid classical and Bayesian” [7]
technique based on conditional expected power (CEP)
[8] to account for the uncertainty in study parameters π1
and π2 when determining the sample size of a superiority
clinical trial. Unlike traditional power, which is calcu-
lated assuming the truth of a point alternative hypothesis
(π2 − π1 = A) for given values of π1 and π2, CEP condi-
tions on the truth of a composite alternative of superiority
(e.g., π2 − π1 > 0 or π2 > π1). CEP formally incorpo-
rates available prior information on both π1 and π2 into
the power calculations by averaging the traditional power
curve using the product of the prior distribution of π1 and
the conditional prior distribution of π2, p(π2 |π2 > π1), as
the averaging weight. Based on the available prior infor-
mation, the sample size that yields the desired level of CEP
can be used when estimating the required sample size of
the study.
While there has been much research in the area of
Bayesian sample size determination [9–12], the hybrid
classical and Bayesian method presented here aligns more
with the ideas found in traditional frequentist sample
size determination. Unlike traditional frequentist meth-
ods, however, we do not assume that the true param-
eters under the alternative hypothesis are known. This
assumption rarely holds; typically, parameter values are
estimated from early phase or pilot studies, studies of
the intervention in different populations, or studies of
similar agents in the current population [13, 14]. Thus,
there is uncertainty surrounding the estimation of these
population parameters and natural prior distributions of
plausible values of these parameters that should be incor-
porated into the assessment of a trial’s power. Our method
incorporates knowledge on the magnitude and uncer-
tainty in the parameters into the traditional frequentist
notion of power through explicit prior distributions on
these unknown parameters to give CEP. As discussed in
the “Methods” Section, CEP is not only well behaved, but
it allows us to maintain a definition of power that intu-
itively converges to the traditional definition. Bayesian
methodology is used only during the study design to
allow prior information, through the prior distributions,
to inform a choice for the sample size. Traditional type
I and type II error rates, which have been accepted in
practice, are maintained, and inferences are based on the
likelihood of the data. The probability of achieving a tar-
get value of power using this method is compared to the
performance of a traditional design. It is our hope that this
formal method for incorporating prior knowledge into the
study design will form the basis of thoughtful discussion
about the feasibility of the study in order to reduce the
number of poorly designed, underpowered studies that
are conducted.
Methods
CEP for dichotomous outcome
Suppose that the study endpoint is dichotomous so that
the probability (risk) of experiencing the event of inter-
est in group 2 (the experimental treatment group), π2, is
compared to that in group 1 (the control group), π1. The
responses (i.e., the number of successes) in each group
follow a binomial distribution. Assume that after n obser-
vations in each independent group or N = 2n total
observations, the two-sample Z-test of proportions is per-
formed to test the null hypothesis H0 : π2 = π1 (i.e.,
π2−π1 =  = 0) versus the two-sided alternative hypoth-
esis H1 : π2 = π1 (i.e., π2 − π1 =  = 0), where π2 > π1
indicates benefit of the experimental treatment over the
control. The test is based on the test statistic T = p2 − p1,
or the difference in the proportion of successes in each
sample. Under H0 : π2 = π1 = π ,T ·∼ N(0, σ0) in large
samples, where σ0 is the standard deviation of the nor-
mal distribution. Assuming equal sample sizes n in each
group gives σ0 = √2π(1 − π)/n, where π = (π1 + π2)/2.
In this setting, H0 is rejected at the α-level of significance
if |T | ≥ z1−α/2 σˆ0, where z1−α/2 is the critical value for
lower tail area 1−α/2 of the standard normal distribution
and π is estimated by p = (p1 + p2)/2 in σˆ0. A positive
conclusion, D1, occurs if Z = T/σˆ0 ≥ z1−α/2 .
Under H1 : π2 − π1 = A,T ·∼ N(A, σ1),
where σ1 = √(π2(1 − π2) + π1(1 − π1))/n. Thus, the
traditional power of this test to detect the hypothesized
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difference corresponding to values of π1 and π2 under
H1 is
P(D1 |π1,π2) = 
[√
N |π2 − π1| − 2z1−α/2
√
π(1 − π)√
2π2(1 − π2) + 2π1(1 − π1)
]
= 1 − β ,
(1)
where[·] is the standard normal cumulative distribution
function. Since the traditional power curve is discontinu-
ous at π2 = π1 for a two-sided test, we assume a successful
outcome or π2 > π1 when calculating power; thus, |π2 −
π1| = π2 − π1 in (1). One may plot the power func-
tion for fixed N and π1 over values of π2 or equivalently
over values of π2 − π1 to give the traditional power curve.
Figure 1 shows the traditional power surfaces for N = 48
and for N = 80 with hypothesized values of π2 = 0.7 and
π1 = 0.3. Power curves for fixed π2 = 0.7 and variable
π1 and for fixed π1 = 0.3 and variable π2 are highlighted.
Sample size is chosen to give high traditional power (e.g.,
0.80 ≤ 1 − β ≤ 0.90) to detect an effect at least as large
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The traditional power curve does not account for
the uncertainty associated with the unknown popula-
tion parameters π2 and π1 and does not indicate if the
planned sample size is adequate given this uncertainty.
Average or expected power (EP) was developed as a way
to use the distribution of prior beliefs about the unknown
parameters to provide an overall predictive probability
Fig. 1 Traditional power surfaces when hypothesized values of
π1 = 0.3 and π2 = 0.7 for N = 48 and N = 80
of a positive conclusion [8, 9, 15–24]. EP, also known
as assurance [20], probability of study success [23], or
Bayesian predictive power [24], averages the traditional
power curve using the prior distributions for the unknown
parameters to weight the average without restricting the
prior distributions to assume treatment superiority. In the
case of a binomial response, assuming π1 and π2 are inde-
pendent yields a special case of the general multivariate
formulation which allows the joint distribution p(π1,π2)
to be factored into the product of the two prior distribu-
tions p(π1) and p(π2). Thus, the traditional power curve
P(D1 |π2,π1) is averaged using the product of the prior
distributions for π2 and π1, p(π2) and p(π1), respectively,







P(D1 |π1,π2) p(π2) p(π1) dπ2 dπ1.
Expected power conditional on the experimental treat-
ment’s superiority, π2 > π1, is known as conditional
expected power (CEP) [8]. Unlike EP, CEP is found by
using the conditional prior distribution for π2, p(π2 |π2 >
π1), in the averaging weight. Since this conditional prior
is now dependent on π1 and equals zero when π2 ≤ π1, to
ensure integration to 1 when P(π1 > π2) > 0, the condi-
tional prior is scaled by the normalization factor P(π2 >
π1)−1, or the inverse probability of the experimental treat-





















p (π1) p (π2) dπ2dπ1. (4)
The unconditional prior distributions p(π1) and p(π2)
are defined such that π1 /∈ [ 0, 1]⇒ p(π1) = 0 and π2
/∈ [0, 1]⇒ p(π2) = 0 (e.g., beta or uniform(0, 1) distribu-
tions).
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Note, any appropriate sample size and power formu-
las may be used to evaluate CEP in (5). For example,
continuity-corrected versions of (2) or the arcsine approx-
imation [25, 26] may alternatively be utilized instead of (2)
to determine sample size, while related power formulas
may be used instead of (1) for CEP calculations.
To evaluate CEP under a proposed design, find N in
(2) for the hypothesized values of π1 and π2, significance
level α, and traditional power level 1 − β . Numerical
integration may then be used to evaluate CEP (5) for
the assumed prior distributions p(π1) and p(π2). If CEP
for the proposed design is less than 1 − β , the study is
expected to be underpowered under the treatment superi-
ority assumption, and if the CEP is greater than 1− β , the
study is expected to be overpowered. To ensure that the
study is expected to be appropriately powered under the
treatment superiority assumption, an iterative search pro-
cedure can be used to find the value of the sample size N
in (5) that gives CEP equal to the threshold of traditional
power 1 − β . The value of N that achieves this desired
level is denotedN∗. As in traditional power, we would like
the probability of detecting a difference when a positive
difference exists to be high (i.e., 0.80 ≤ 1 − β ≤ 0.90).
Pseudo-code 1 outlines the steps for this process.
If the prior distributions put all their mass at a sin-
gle positive point, essentially becoming a traditional
point alternative hypothesis, EP and CEP reduce to
Pseudo-Code 1: Find N∗
input :
prior density function p(π1) of proportion
π1 ∈ [0, 1]
prior density function p(π2) of proportion
π2 ∈ [0, 1]
critical value z1−α/2
power function (·) of π1,π2, z1−α/2 , and
sample size N
target CEP value 1 − β
output: N∗ such that CEP(N∗ − 1) < 1 − β and




while CEP < 1 − β do
N = N + 1












the traditional formulation of power. However, for prior
distributions where P(π1 > π2) > 0, CEP will be greater
than EP, with CEP approaching 1 and EP approaching














































p(π2) p(π1) dπ2 dπ1
= P(π2 > π1)
When there is no doubt of a beneficial effect (i.e., P(π2 >
π1) = 1), CEP equals EP.
Previous work in this area almost exclusively uses
expected power P(D1) to account for uncertainty in study
design parameters [8, 9, 15–24], and finds the sample size
that gives the desired level of P(D1). Our preference for
using CEP as opposed to EP to inform the design of a
study is twofold. EP gives the predictive probability of a
positive conclusion, regardless of the truth of the alterna-
tive hypothesis. CEP, however, is conceptually analogous
to traditional power in that it is conditional on the truth
of the benefit of the experimental treatment, which pro-
vides a more familiar framework for setting the desired
level of CEP for a study. Secondly, if P(π1 > π2) > 0, then
EP will not approach 1 as the sample size goes to infinity
because limN→∞ P(D1) = 1 − P(π1 > π2). CEP, how-
ever, is conditioned on π2 > π1, so it approaches 1 as the
sample size increases since limN→∞ P(D1 |π2 > π1) =
1 − P(π1 > π2)
P(π2 > π1)
= 1. Thus, CEP is also moremathemati-
cally analogous to traditional power in that the probability
of correctly reaching a positive conclusion is assured as
the sample size goes to infinity.
Prior distributions
The prior distributions p(π1) and p(π2) reflect the cur-
rent knowledge about the response rate in each treatment
group before the trial is conducted. In the design phase
of a clinical trial, a review of the literature is often per-
formed. This collection of prior evidence forms a nat-
ural foundation for specifying the prior distributions.
Historical data are commonly pooled using traditional
meta-analysis techniques to calculate an overall point
estimate [27, 28]; however, a Bayesian random-effects
meta-analysis [29–31] may be more appropriate when the
goal is to hypothesize a prior distribution. The priors
can also incorporate the pre-trial consensus of experts in
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the field [9] or Phase II trial data [22]. Translating and
combining prior evidence and opinions to form a prior
distribution is often hailed as the most challenging part of
using a Bayesian framework [7], and several works [32–35]
describe techniques for eliciting a prior distribution.
A beta distribution, which is defined on the interval
[0, 1], can be used to describe initial beliefs about the
parameters π1 and π2. If πj ∼ Beta(a, b), then
p(πj) = (a + b)
(a) (b)π
a−1
j (1 − πj)b−1
where shape parameters a > 0 and b > 0. The mean,
variance, and mode of the prior distribution are given by:
μ = a/(a + b), τ 2 = ab/((a + b)2(a + b + 1)), and
m = (a − 1)/(a + b − 2) for a, b > 1, respectively. For
fixed μ, larger values of a and b decrease τ 2. One may
choose the shape parameters a and b by fixing the mean
and variance of the distribution at fixed values μ and τ 2,
which yields a = μ2(1 − μ)/τ 2 − μ and b = a(1 − μ)/μ.
For skewed distributions, onemay wish to describe central
tendency using the mode m rather than the mean. Under
a traditional design, the difference in modes, m2 − m1, is
a natural estimate for the hypothesized difference in pro-
portions. When fixing m and τ 2, the corresponding value
of b may be found by solving the general cubic equation
Ab3 + Bb2 + Cb + D = 0, with coefficients
A = − m
3
(m − 1)3 +
3m2
(m − 1)2 −
3m
(m − 1) + 1
B = 6m
3 − 3m2
(m − 1)3 +
−11m2 + 6m
(m − 1)2 +
4m + m
τ 2 − 3
(m − 1) + 1
C = −12m
3 + 12m2 − 3m
(m − 1)3 +
8m2 − 10m + 3
(m − 1)2 −




3 − 12m2 + 6m − 1
(m − 1)3 +
4m2 − 4m + 1
(m − 1)2 .
The corresponding value of a is given by a = 2m−mb−1m−1 .
(Table 2 in the Appendix reports the values of a and b for
given m and τ 2.) Notice that for a given variance τ 2, the
value of a when the mode = m equals the value of b when
the mode = 1 − m. Thus, whenm = 0.5, a = b.
A uniform prior distribution may also be assumed for
πj with limits within the interval [0, 1]. The uniform prior
has lower bound a and upper bound b, or πj ∼ U(a, b),
and is constant over the range [a, b]. The prior is cen-
tered at μ = (a + b)/2 with variance τ 2 = (b − a)2/12.
The non-informative prior distribution that assumes
no values of πj are more probable than any others is
U(0, 1) ≡ Beta(1, 1). One may also restrict the range
of the uniform distribution to focus on smaller ranges
for π1 and π2. Rather than setting the lower and upper
bounds of the uniform, one may set the mean μ < 1
and variance τ 2 < min(μ
2, (1 − μ)2)
3 of the prior
distribution, which gives lower bound a = μ − √3 τ 2 and
upper bound b = μ + √3 τ 2. Again, under a traditional
design, the difference in means μ2 − μ1 is a natural
estimate for the hypothesized difference in proportions
when presented with uniform prior evidence. (Table 3
in the Appendix reports the values of a and b for given
μ and τ 2.) Notice that restrictions exist for the vari-
ances assumed for certain means to maintain bounds
between [0, 1].
Results
The procedures described in the “Methods” Section were
applied to a set of notional scenarios to compare tradi-
tionally designed studies to those designed using CEP. The
integration step of Pseudo-code 1 was approximated using
Riemann sums with step size 0.0001.
An example scenario assumed beta-distributed pri-
ors for π1 and π2, such that π1 ∼ Beta(6.62, 14.11)
and π2 ∼ Beta(14.11, 6.62). For this scenario, a tra-
ditionally designed study would select a sample size
of N = 48 based on (2) to achieve 80% power and
a two-sided type I error of 5%, with hypothesized
values of π1 = mode (Beta(6.62, 14.11)) = 0.3 and
π2 = mode (Beta(14.11, 6, 62)) = 0.7. However, based
on the assumed prior distributions, a study with a sam-
ple size of 48 could achieve less than 80% power when
π1 = 0.3 or π2 = 0.7. In fact, based on (5), the study with
sample size N = 48 would give CEP = 67.8%. Figure 2a
displays the joint distribution of π1 and π2, conditional on
π2 > π1, and highlights the region where power would be
less than 80% under a traditional design when the sample
size is N = 48. For this scenario, the study with sample
size N = 48 would achieve power less than the target
value in more than 56% of instances when π2 > π1.
For the same scenario, a CEP-designed study would
select a sample size of N∗ = 80 based on Pseudo-code 1
to achieve 80% CEP with a two-sided type I error of 5%.
Figure 2b displays the joint distribution of π1 and π2, con-
ditional on π2 > π1, and highlights the region where
power would be less than 80% under a CEP design when
the sample size is N∗ = 80. For this scenario, the study
with sample size N∗ = 80 would achieve power less than
the target value in approximately 33% of instances when
π2 > π1. Note that the intersection of the two regions cor-
responds to values of π1 and π2 that give power from (1)
equal to 80% with sample size N = 80.
The probability of achieving power at least equal to the
target value, conditional on the experimental treatment’s
superiority (π2 > π1), is here termed the performance of
the design. While CEP provides a point estimate of power
under the treatment superiority assumption, performance
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Fig. 2 Conditional joint prior density p(π1)p(π2|π2 > π1) for π1 ∼ Beta(6.62, 14.11) and π2 ∼ Beta(14.11, 6.62). a Highlighting region where power
< 80% under a traditional design. b Highlighting region where power < 80% under a CEP design
indicates how robust the design is. The performance of




























Thus, the traditionally designed study from the example
scenario produced a performance of (100 − 56)% = 44%,
while the CEP design, which explicitly accounts for uncer-
tainty, produced a more robust performance of (100 −
33)% = 67%. However, this increase in performance
required an increase in sample size from N = 48 to N∗ =
80. The increase in performance divided by the increase
in sample size is here termed the marginal benefit for the
scenario due to CEP. The marginal benefit for the example
scenario due to CEP is given by (67 − 44)%/(80 − 48) =
0.71%. If there is no uncertainty in the design parameters,
then there would be no marginal benefit due to CEP, since
the probability of achieving less than the target power
would be assumed 0 for a traditionally designed study and
the CEP-designed study would giveN∗ = N . On the other
hand, if the uncertainty in the design parameters is very
large, the marginal benefit may approach 0, since the CEP-
designed study could giveN∗ >> N with limited increase
in performance. This is important to consider, since a
very small marginal benefit could make it impractical to
achieve a desired value for CEP or a desired threshold of
performance.
Since the performance and marginal benefit result from
the prior distributions of π1 and π2, several notional sce-
narios were evaluated to explore the relationship between
prior distributions, CEP, and performance. Tables 4, 5
and 6 in the Appendix display the results of several sce-
narios that assumed Beta-distributed priors for π1 and π2.
The mode and variance of p(πj), j = 1, 2, are denoted
mj and τ 2j , respectively. The procedure for generating the
results from Table 4 in the Appendix, for which τ 21 = τ 22 ,
is given below:
1. The modes,m1 andm2, and variances, τ 21 = τ 22 , were
used to hypothesize a beta prior distribution for π1
and π2, respectively.
2. For each pair of prior distributions (p(π1), p(π2))
considered:
(a) Traditional sample size is found using (2) by
setting the hypothesized values of π1 and π2
equal to the mode of each prior,m1 andm2,
respectively. Two-sided type I error α = 0.05
and traditional power 1 − β = 0.80 are
assumed. Traditional sample size is denoted
Nˆ . If Nˆ is odd, the sample size is increased by
1 to provide equal sample size for both groups.
(b) The CEP of the traditional design is found
using (5), with N = Nˆ , two-sided α = 0.05,
and 1 − β = 0.80.
(c) The performance of the traditional design is
found using (6), with N = Nˆ , two-sided
α = 0.05, and 1 − β = 0.80.
(d) The smallest sample size for which CEP
evaluates to ≥ 1 − β is found using
Pseudo-Code 1 and is denoted N∗. If N∗ is
odd, the sample size is increased by 1 to
provide equal sample size for both groups.
(e) The probability of a positive treatment effect,
P(π2 > π1), is found using (4) with Riemann
sum integral approximations.
(f) The conditional expected difference,
E(π2 − π1|π2 > π1), is found using Riemann







(g) The performance of the CEP design is found
using (6), with N = N∗, two-sided α = 0.05,
and 1 − β = 0.80.
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(h) The marginal benefit due to CEP for the
scenario is found by dividing the difference
between the CEP design performance and the
traditional design performance by the
difference between the CEP sample size and
the traditional sample size, N∗ − Nˆ .
Table 4 in the Appendix shows that when m2 − m1 >
1/3, the performance of the traditional design decreases
as τ 21 = τ 22 increases. This is explained by the fact that the
conditional expected difference is less than the hypoth-
esized difference that was used in the traditional design
sample size calculation. This occurs for m2 − m1 > 1/3
since both prior distributions are approaching U(0, 1) as
τ 21 = τ 22 increases, and E(π2 − π1|π2 > π1) = 1/3 for
π1,π2 ∼ U(0, 1). Thus, when m2 − m1 < 1/3, the per-
formance of the traditional design increases as τ 21 = τ 22
increases since the hypothesized difference is less than
the limit of the conditional expected difference. When
m2 − m1 is smaller than E(π2 − π1|π2 > π1), CEP will be
high for a traditional design with hypothesized difference
m2 −m1, since it is designed to detect a difference smaller
than the expected difference.
The procedure was also applied to scenarios where τ 21 =
0.001 and τ 22 > 0.001 (Table 5 in the Appendix) and sce-
narios where τ 21 = 0.08 and τ 22 < 0.08 (Table 6 in the
Appendix), corresponding to small and large uncertainty,
respectively, in the proportion experiencing the outcome
in the control group. Table 5 in the Appendix shows that
the performance of the traditional design is similar to the
performance seen in Table 4 in the Appendix. However,
when τ 21 is fixed at 0.001,E(π2 − π1|π2 > π1) begins
nearm2 − m1 and approaches (1 − m1)/2 as τ 22 increases
because p(π2|π2 > π1) is approaching U(m1, 1). Thus,
when m2 − m1 > (1 − m1)/2, the performance of the
traditional design decreases as τ 22 increases, and when
m2 −m1 < (1−m1)/2, the performance of the traditional
design increases as τ 22 increases.
When τ 21 is fixed at 0.08,E(π2−π1|π2 > π1) approaches
1/3 from m2/2. If E(π2 − π1|π2 > π1) is increasing
towards 1/3 as τ 22 increases, then the performance of the
traditional design will increase. If E(π2 − π1|π2 > π1)
decreases towards 1/3 as τ 22 increases, then the perfor-
mance of the traditional design will decrease. If m2/2 >
1/3, then the performance of the traditional design will
decrease as τ 22 increases. This happens because, as τ 22
increases, the hypothesized difference is decreasing from
m2/2 to 1/3. The behavior of the traditional design is
summarized in Table 1.
Excursions with uniform priors were performed. Table 7
in the Appendix shows that the performance of a tra-
ditional design under a uniform prior is similar to the
performance observed in Table 4 in the Appendix. How-
ever, fewer trends are visible because the parameters of
Table 1 Analysis of traditional design performance
Uncertainty m2 − m1 Performance
τ 21 = τ 22 < 1/3 Increases as τ 21 = τ 22 increases
> 1/3 Decreases as τ 21 = τ 22 increases
τ 21 small < (1 − m1)/2 Increases as τ 22 increases
> (1 − m1)/2 Decreases as τ 22 increases
τ 21 large > 2/3 − m1 Increases as τ 22 increases
< 2/3 − m1 Decreases as τ 22 increases
the uniform distribution are more restricted than the
parameters of the beta distribution.
As expected, the performance of the CEP design
changes minimally as τ 21 = τ 22 increases, since N∗ is cho-
sen to explicitly account for changes in τ 21 = τ 22 . Note,
N∗ is directly tied to E(π2 − π1|π2 > π1): N∗ increases
as the conditional expected difference decreases, and
N∗ decreases as the conditional expected difference
increases. This occurs because increasing the variability
can increase the conditional expected difference if the
resulting conditional priors give more relative weight to
larger differences and less relative weight to smaller differ-
ences compared to the unconditional priors. This is more
likely to occur whenm1 is large, since increasing the vari-
ability when m1 is large will make smaller values of π1
more likely due to the condition that π2 > π1. Similarly,
whenm2 is small, larger values of π2 are more likely under
the assumption that π2 > π1.
The marginal benefit due to CEP is greatest for small
values of τ 21 = τ 22 . This is so because the relative
difference between Nˆ and N∗ is smallest when the
uncertainty is low (i.e., when the traditional assumptions
closely approximate the CEP assumptions). However, the
marginal benefit due to CEP decreases minimally or
remains constant as the uncertainty increases because the
difference in performance is always less than 1, while the
difference in sample size, N∗ − Nˆ , can be greater than
200 in some cases. Furthermore, as τ 21 = τ 22 increases,
the performance of the traditional design can improve
even though Nˆ remains constant, while N∗ may have to
increase to maintain the performance of the CEP design.
When τ 21 is fixed at 0.001, the performance of the CEP
design remains stable at approximately 0.7. However, the
marginal benefit is greater with fixed, low uncertainty in
π1 compared with the changing uncertainty in Table 4 in
the Appendix. The sample size required to achieve CEP of
1−β with fixed τ 21 is reduced compared to scenarios with
changing τ 21 . This is because uncertainty in the control
group is small, which indicates that reducing the uncer-
tainty in the control parameter can increase the benefit of
CEP to the study.
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When τ 21 is fixed at 0.08, the performance of the CEP
design remains stable at approximately 0.71. However, the
marginal benefit is very small becauseN∗ is always greater
than that in Table 4 or Table 5 in the Appendix due to the
larger uncertainty in π1. Again, this demonstrates that it
is beneficial to minimize the uncertainty in π1 to increase
the marginal benefit.
Note that for small differences in m2 − m1 and any
large variance, the CEP design can reduce the sample
size from the value determined from a traditional design.
The reason is that increased uncertainty under the treat-
ment superiority assumption increases the likelihood of
differences greater thanm2 − m1.
Discussion
Many underpowered clinical trials are conducted with
limited justification for the chosen study parameters used
to determine the required sample size [36, 37] with
scientific, economic, and ethical implications [36, 38].
While sample size calculations based on traditional power
assume no uncertainty in the study parameters, the hybrid
classical and Bayesian procedure presented here formally
accounts for the uncertainty in the study parameters by
incorporating the prior distributions for π1 and π2 into
the calculation of conditional expected power (CEP). This
method allows available evidence on both the magnitude
and the variability surrounding the parameters to play a
formal role in determining study power and sample size.
In this paper, we explored several notional scenarios to
compare the performance of the CEP design to that of a
design based on traditional power. We show that if there
is uncertainty in the study parameters and a distribution
of plausible values for π1 and π2, the performance of the
CEP design is more consistent and robust than that of tra-
ditional designs based on point estimates for the study
parameters. Traditional sample size calculations based on
point estimates for the hypothesized study parameters
tend to underestimate the required sample size needed to
account for the uncertainty in the parameters.
The scenarios demonstrate that reducing uncertainty
in the control parameter π1 can lead to greater ben-
efit from the CEP-designed study, because the relative
difference between Nˆ and N∗ is smallest when uncer-
tainty is low. Therefore, it is worthwhile to use historical
information to reduce the variability in the control group
proportion rather than focusing only on the prior for
the experimental treatment group. Nonetheless, when
there is significant overlap between the prior distribu-
tions and a small hypothesized difference m2 − m1,
traditional study designs can be overpowered under
the treatment superiority assumption compared to the
CEP design, and the CEP design would result in a
smaller sample size. This happens because increased
uncertainty under the treatment superiority assumption
increases the relative likelihood of differences greater
thanm2 − m1.
In the scenarios we evaluated, the performance of the
traditional design was highly dependent on the prior dis-
tributions but exhibited predictable behavior. The CEP
design, however, consistently generated performance near
70% across all scenarios. This indicates that power greater
than the target 1 − β would not be uncommon for a CEP
design. This begs the question of whether or not 1 − β
is an appropriate target for CEP, since it could apparently
lead to overpowered studies. To avoid this issue, one may
use a lower target for CEP or instead design the study
using a target value of performance and use our itera-
tive N∗ search to find the design that achieves acceptable
performance.
Additionally, when comparing the method based on
CEP to similar methods based on expected power, the
sample size from a CEP design will always be less than
or equal to the sample size required to achieve equiv-
alent EP. While pure Bayesian methods of sample size
determination that compute prior effective sample size to
count the information contained in the prior towards the
current study will generally yield a smaller sample size
than traditional frequentist methods [10], themethod pre-
sented here does not assume that prior information will
be incorporated into the final analysis.
Conclusions
The hybrid classical and Bayesian procedure presented
here integrates available prior information about the study
design parameters into the calculation of study sample
size for a binary endpoint. This method allows prior
information on both the magnitude and uncertainty sur-
rounding the parameters π1 and π2 to inform the design of
the current study through the use of conditional expected
power. When there is a distribution of plausible study
parameters, the design based on conditional expected
power tends to outperform the traditional design. Note
that if the determined sample size N∗ is greater than what
can be feasibly recruited in the proposed trial, this may
indicate excessive uncertainty about the study parameters
and should encourage serious discussion concerning the
advisability of the study. Thus, we do not recommend that
N∗ be blindly used as the final study sample size, but we
hope that this method encourages a careful synthesis of
the prior information andmotivates thoughtful discussion
about the feasibility of the study in order to reduce the
number of poorly designed, underpowered studies that
are conducted.
Appendix
Table 2 presents the values of shape paramaters [a, b] for
given m and τ 2 for the beta distribution. Table 3 reports
the values of minimum and maximum parameters [a, b]
for given μ and τ 2 for the uniform distribution.
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Table 4 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = τ 22 . Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed
Traditional design CEP design
(m1,m2) τ 21 = τ 22 Nˆ Performance CEP N∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
(0.1, 0.9) 0.001 10 0.797 0.518 12 0.742 0.783 1 0.1120
0.01 10 0.622 0.242 16 0.627 0.674 1 0.0642
0.02 10 0.508 0.164 26 0.673 0.585 0.993 0.0318
0.03 10 0.433 0.123 40 0.687 0.519 0.965 0.0188
0.04 10 0.381 0.099 60 0.698 0.469 0.915 0.0120
0.05 10 0.342 0.082 86 0.705 0.429 0.846 0.0082
0.06 10 0.311 0.070 120 0.710 0.397 0.761 0.0058
0.07 10 0.285 0.060 160 0.713 0.369 0.662 0.0044
0.08 10 0.262 0.052 214 0.716 0.342 0.545 0.0033
(0.1, 0.8) or (0.2, 0.9) 0.001 14 0.804 0.559 14 0.559 0.688 1 0
0.01 14 0.656 0.314 22 0.623 0.602 1 0.0386
0.02 14 0.553 0.237 34 0.674 0.529 0.989 0.0218
0.03 14 0.486 0.195 52 0.692 0.476 0.953 0.0131
0.04 14 0.439 0.168 76 0.702 0.438 0.896 0.0086
0.05 14 0.405 0.149 102 0.706 0.408 0.823 0.0063
0.06 14 0.377 0.134 134 0.711 0.383 0.740 0.0048
0.07 14 0.353 0.121 172 0.713 0.361 0.646 0.0037
0.08 14 0.331 0.110 218 0.716 0.340 0.540 0.0030
(0.1, 0.7) or (0.3, 0.9) 0.001 20 0.814 0.616 20 0.616 0.590 1 0
0.01 20 0.670 0.364 30 0.636 0.518 0.999 0.0272
0.02 20 0.578 0.295 48 0.677 0.463 0.979 0.0136
0.03 20 0.523 0.260 72 0.697 0.426 0.931 0.0084
0.04 20 0.488 0.238 98 0.705 0.401 0.866 0.0060
0.05 20 0.462 0.223 126 0.708 0.382 0.792 0.0046
0.06 20 0.442 0.211 154 0.712 0.367 0.712 0.0037
0.07 20 0.424 0.200 186 0.714 0.353 0.627 0.0031
0.08 20 0.407 0.189 222 0.716 0.338 0.534 0.0026
(0.2, 0.8) 0.001 20 0.800 0.537 22 0.644 0.593 1 0.0537
0.01 20 0.676 0.372 30 0.643 0.530 0.999 0.0271
0.02 20 0.588 0.308 48 0.680 0.474 0.982 0.0133
0.03 20 0.532 0.272 70 0.695 0.435 0.936 0.0085
0.04 20 0.495 0.247 94 0.703 0.408 0.872 0.0062
0.05 20 0.467 0.229 122 0.709 0.387 0.798 0.0047
0.06 20 0.445 0.215 152 0.711 0.370 0.717 0.0038
0.07 20 0.425 0.202 184 0.714 0.354 0.630 0.0031
0.08 20 0.407 0.189 222 0.716 0.339 0.534 0.0026
(0.1, 0.6) or (0.4, 0.9) 0.001 28 0.804 0.572 28 0.572 0.491 1 0
0.01 28 0.655 0.368 48 0.660 0.430 0.996 0.0146
0.02 28 0.578 0.319 76 0.689 0.393 0.958 0.0077
0.03 28 0.540 0.299 106 0.701 0.374 0.895 0.0052
0.04 28 0.518 0.290 132 0.706 0.362 0.824 0.0040
0.05 28 0.504 0.285 158 0.710 0.355 0.752 0.0033
0.06 28 0.494 0.281 180 0.713 0.349 0.680 0.0028
0.07 28 0.486 0.278 202 0.714 0.343 0.606 0.0025
0.08 28 0.476 0.272 226 0.715 0.336 0.528 0.0022
(0.2, 0.7) or (0.3, 0.8) 0.001 30 0.803 0.558 30 0.558 0.494 1 0
0.01 30 0.682 0.412 46 0.653 0.446 0.998 0.0151
0.02 30 0.609 0.365 72 0.686 0.410 0.966 0.0076
0.03 30 0.570 0.342 100 0.700 0.388 0.907 0.0051
0.04 30 0.546 0.328 126 0.706 0.374 0.837 0.0039
0.05 30 0.529 0.317 150 0.710 0.363 0.763 0.0033
0.06 30 0.515 0.309 174 0.713 0.354 0.688 0.0028
0.07 30 0.503 0.300 198 0.714 0.346 0.611 0.0025
0.08 30 0.491 0.291 226 0.716 0.337 0.529 0.0022
(0.1, 0.5) or (0.5, 0.9) 0.001 40 0.781 0.488 42 0.566 0.392 1 0.0393
0.01 40 0.627 0.358 80 0.675 0.343 0.985 0.0079
0.02 40 0.573 0.335 124 0.697 0.326 0.918 0.0043
0.03 40 0.553 0.334 160 0.706 0.322 0.841 0.0031
0.04 40 0.546 0.339 182 0.709 0.324 0.769 0.0026
0.05 40 0.545 0.346 200 0.712 0.327 0.703 0.0023
0.06 40 0.545 0.353 210 0.713 0.331 0.642 0.0021
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Table 4 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = τ 22 . Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed (Continued)
Traditional design CEP design
(m1,m2) τ 21 = τ 22 Nˆ Performance CEP N∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
0.07 40 0.546 0.359 220 0.715 0.334 0.584 0.0020
0.08 40 0.545 0.362 230 0.716 0.334 0.522 0.0019
(0.2, 0.6) or (0.4, 0.8) 0.001 46 0.791 0.518 48 0.587 0.395 1 0.0345
0.01 46 0.668 0.422 80 0.668 0.360 0.991 0.0072
0.02 46 0.617 0.401 118 0.694 0.343 0.933 0.0041
0.03 46 0.597 0.397 150 0.704 0.339 0.860 0.0030
0.04 46 0.588 0.397 172 0.709 0.338 0.787 0.0025
0.05 46 0.584 0.399 190 0.712 0.338 0.719 0.0022
0.06 46 0.580 0.400 202 0.713 0.337 0.654 0.0020
0.07 46 0.577 0.400 216 0.714 0.337 0.589 0.0018
0.08 46 0.572 0.398 230 0.715 0.335 0.523 0.0017
(0.3, 0.7) 0.001 48 0.793 0.524 50 0.558 0.396 1 0.0167
0.01 48 0.678 0.438 80 0.665 0.365 0.992 0.0071
0.02 48 0.629 0.419 118 0.695 0.349 0.938 0.0039
0.03 48 0.610 0.415 146 0.704 0.344 0.866 0.0029
0.04 48 0.601 0.415 168 0.709 0.342 0.794 0.0024
0.05 48 0.595 0.415 186 0.711 0.341 0.724 0.0021
0.06 48 0.591 0.415 200 0.714 0.340 0.658 0.0020
0.07 48 0.586 0.413 214 0.715 0.338 0.591 0.0018
0.08 48 0.580 0.409 230 0.715 0.335 0.523 0.0017
(0.1, 0.4) or (0.6, 0.9) 0.001 64 0.763 0.461 72 0.588 0.292 1 0.0159
0.01 64 0.612 0.377 156 0.689 0.262 0.951 0.0034
0.02 64 0.588 0.381 216 0.705 0.265 0.850 0.0021
0.03 64 0.588 0.397 242 0.709 0.276 0.768 0.0018
0.04 64 0.594 0.414 250 0.712 0.289 0.703 0.0016
0.05 64 0.603 0.432 250 0.714 0.302 0.649 0.0015
0.06 64 0.613 0.449 246 0.715 0.314 0.603 0.0015
0.07 64 0.622 0.464 238 0.715 0.325 0.560 0.0014
0.08 64 0.628 0.474 234 0.715 0.332 0.516 0.0014
(0.2, 0.5) or (0.5, 0.8) 0.001 78 0.776 0.491 84 0.584 0.296 1 0.0154
0.01 78 0.654 0.441 158 0.686 0.277 0.964 0.0031
0.02 78 0.635 0.450 210 0.703 0.282 0.872 0.0019
0.03 78 0.635 0.465 232 0.709 0.292 0.791 0.0016
0.04 78 0.640 0.480 238 0.711 0.302 0.724 0.0014
0.05 78 0.647 0.493 240 0.713 0.312 0.666 0.0014
0.06 78 0.653 0.504 238 0.714 0.321 0.615 0.0013
0.07 78 0.658 0.514 234 0.715 0.328 0.566 0.0013
0.08 78 0.661 0.520 234 0.716 0.332 0.517 0.0013
(0.3, 0.6) or (0.4, 0.7) 0.001 84 0.775 0.483 92 0.584 0.297 1 0.0126
0.01 84 0.666 0.457 162 0.683 0.283 0.968 0.0029
0.02 84 0.649 0.471 210 0.702 0.289 0.881 0.0018
0.03 84 0.652 0.489 228 0.708 0.300 0.802 0.0015
0.04 84 0.658 0.504 234 0.712 0.309 0.735 0.0014
0.05 84 0.663 0.516 234 0.713 0.318 0.676 0.0013
0.06 84 0.668 0.525 232 0.714 0.324 0.621 0.0013
0.07 84 0.671 0.532 232 0.715 0.329 0.569 0.0012
0.08 84 0.672 0.536 234 0.716 0.333 0.517 0.0012
(0.1, 0.3) or (0.7, 0.9) 0.001 124 0.736 0.453 152 0.614 0.194 1 0.0057
0.01 124 0.625 0.434 346 0.703 0.193 0.866 0.0012
0.02 124 0.636 0.470 374 0.710 0.216 0.750 0.0010
0.03 124 0.654 0.501 358 0.712 0.239 0.680 0.0009
0.04 124 0.671 0.528 334 0.714 0.261 0.631 0.0009
0.05 124 0.687 0.553 306 0.714 0.281 0.594 0.0009
0.06 124 0.701 0.575 280 0.715 0.300 0.565 0.0009
0.07 124 0.714 0.594 258 0.715 0.317 0.538 0.0009
0.08 124 0.725 0.610 240 0.716 0.330 0.510 0.0009
(0.2, 0.4) or (0.6, 0.8) 0.001 164 0.754 0.487 190 0.605 0.197 1 0.0045
0.01 164 0.667 0.496 372 0.702 0.205 0.887 0.0010
0.02 164 0.683 0.537 380 0.709 0.229 0.774 0.0008
0.03 164 0.701 0.568 356 0.712 0.251 0.702 0.0007
0.04 164 0.716 0.593 326 0.714 0.271 0.650 0.0007
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Table 4 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = τ 22 . Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed (Continued)
Traditional design CEP design
(m1,m2) τ 21 = τ 22 Nˆ Performance CEP N∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
0.05 164 0.730 0.614 300 0.714 0.289 0.609 0.0007
0.06 164 0.742 0.632 276 0.715 0.305 0.574 0.0007
0.07 164 0.752 0.647 254 0.715 0.319 0.543 0.0008
0.08 164 0.760 0.659 240 0.716 0.330 0.511 0.0008
(0.3, 0.5) or (0.5, 0.7) 0.001 186 0.755 0.487 214 0.605 0.198 1 0.0042
0.01 186 0.679 0.513 394 0.700 0.210 0.896 0.0009
0.02 186 0.699 0.560 390 0.709 0.236 0.787 0.0007
0.03 186 0.719 0.594 356 0.712 0.259 0.715 0.0007
0.04 186 0.735 0.620 324 0.713 0.278 0.662 0.0007
0.05 186 0.748 0.640 294 0.714 0.294 0.619 0.0007
0.06 186 0.759 0.656 272 0.715 0.308 0.581 0.0007
0.07 186 0.768 0.669 252 0.715 0.321 0.546 0.0007
0.08 186 0.774 0.679 238 0.716 0.331 0.511 0.0007
(0.4, 0.6) 0.001 194 0.757 0.491 222 0.603 0.198 1 0.0040
0.01 194 0.683 0.518 402 0.700 0.211 0.898 0.0009
0.02 194 0.704 0.567 396 0.709 0.238 0.791 0.0007
0.03 194 0.724 0.602 358 0.712 0.261 0.720 0.0007
0.04 194 0.741 0.628 322 0.713 0.280 0.666 0.0007
0.05 194 0.754 0.648 294 0.714 0.296 0.622 0.0007
0.06 194 0.765 0.664 270 0.715 0.310 0.583 0.0007
0.07 194 0.773 0.677 252 0.715 0.321 0.547 0.0007
0.08 194 0.779 0.686 238 0.716 0.331 0.511 0.0007
(0.1, 0.2) or (0.8, 0.9) 0.001 398 0.683 0.470 676 0.675 0.098 0.981 0.0007
0.01 398 0.712 0.584 794 0.712 0.141 0.708 0.0003
0.02 398 0.750 0.642 618 0.714 0.179 0.626 0.0003
0.03 398 0.775 0.679 504 0.715 0.211 0.586 0.0003
0.04 398 0.794 0.706 424 0.715 0.239 0.562 0.0003
0.05 398 0.809 0.728 364 0.715 0.265 0.544 0.0004
0.06 398 0.822 0.747 316 0.716 0.288 0.530 0.0004
0.07 398 0.833 0.763 276 0.716 0.310 0.518 0.0004
0.08 398 0.843 0.777 244 0.716 0.328 0.505 0.0004
(0.2, 0.3) or (0.7, 0.8) 0.001 588 0.701 0.495 924 0.672 0.100 0.985 0.0005
0.01 588 0.746 0.633 922 0.711 0.149 0.727 0.0002
0.02 588 0.787 0.695 666 0.714 0.188 0.644 0.0002
0.03 588 0.812 0.731 524 0.715 0.218 0.601 0.0003
0.04 588 0.829 0.756 432 0.715 0.245 0.573 0.0003
0.05 588 0.842 0.775 366 0.716 0.269 0.552 0.0003
0.06 588 0.853 0.791 316 0.716 0.291 0.535 0.0003
0.07 588 0.863 0.805 276 0.716 0.311 0.520 0.0003
0.08 588 0.871 0.816 244 0.716 0.328 0.506 0.0003
(0.3, 0.4) or (0.6, 0.7) 0.001 712 0.704 0.500 1100 0.671 0.101 0.986 0.0004
0.01 712 0.756 0.647 1034 0.711 0.153 0.736 0.0002
0.02 712 0.800 0.713 714 0.714 0.193 0.654 0.0005
0.03 712 0.825 0.751 544 0.714 0.224 0.611 0.0002
0.04 712 0.843 0.776 440 0.715 0.250 0.581 0.0002
0.05 712 0.856 0.795 368 0.715 0.273 0.559 0.0002
0.06 712 0.867 0.810 314 0.716 0.294 0.540 0.0002
0.07 712 0.875 0.823 274 0.716 0.312 0.523 0.0002
0.08 712 0.882 0.833 244 0.716 0.329 0.506 0.0003
(0.4, 0.5) or (0.5, 0.6) 0.001 776 0.706 0.502 1190 0.670 0.101 0.986 0.0004
0.01 776 0.760 0.652 1096 0.711 0.154 0.740 0.0002
0.02 776 0.804 0.720 744 0.713 0.195 0.659 0.0002
0.03 776 0.831 0.758 558 0.714 0.226 0.615 0.0002
0.04 776 0.849 0.784 446 0.715 0.253 0.586 0.0002
0.05 776 0.862 0.803 368 0.715 0.275 0.562 0.0002
0.06 776 0.872 0.818 314 0.716 0.295 0.542 0.0002
0.07 776 0.881 0.830 274 0.716 0.313 0.524 0.0002
0.08 776 0.887 0.840 244 0.716 0.329 0.506 0.0002
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Table 5 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = 0.001. Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed
(τ 21 = 0.001) Traditional design CEP design
(m1,m2) τ 22 Nˆ Performance CEP N
∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
(0.1, 0.9) 0.01 10 0.344 0.706 14 0.640 0.728 1 0.0740
0.02 10 0.280 0.639 16 0.615 0.682 1 0.0559
0.03 10 0.239 0.586 20 0.655 0.640 0.999 0.0416
0.04 10 0.208 0.539 24 0.659 0.601 0.997 0.0322
0.05 10 0.184 0.497 30 0.671 0.564 0.991 0.0244
0.06 10 0.163 0.459 38 0.687 0.528 0.979 0.0187
0.07 10 0.144 0.424 50 0.693 0.494 0.955 0.0137
0.08 10 0.127 0.389 70 0.703 0.459 0.913 0.0096
(0.1, 0.8) 0.01 14 0.439 0.748 16 0.586 0.656 1 0.0735
0.02 14 0.389 0.697 20 0.623 0.624 1 0.0390
0.03 14 0.353 0.652 24 0.651 0.592 0.999 0.0298
0.04 14 0.324 0.611 28 0.667 0.561 0.997 0.0245
0.05 14 0.299 0.574 34 0.674 0.533 0.990 0.0187
0.06 14 0.278 0.540 44 0.687 0.505 0.975 0.0136
0.07 14 0.259 0.509 56 0.695 0.480 0.950 0.0104
0.08 14 0.241 0.480 72 0.703 0.455 0.910 0.0080
(0.1, 0.7) 0.01 20 0.507 0.773 22 0.603 0.572 1 0.0481
0.02 20 0.466 0.732 26 0.623 0.552 1 0.0262
0.03 20 0.438 0.695 30 0.643 0.532 0.999 0.0205
0.04 20 0.416 0.662 36 0.667 0.513 0.995 0.0157
0.05 20 0.397 0.633 42 0.680 0.494 0.986 0.0129
0.06 20 0.382 0.607 52 0.691 0.478 0.969 0.0097
0.07 20 0.369 0.585 62 0.696 0.464 0.943 0.0078
0.08 20 0.358 0.566 76 0.705 0.450 0.906 0.0062
(0.2, 0.8) 0.01 20 0.430 0.734 24 0.601 0.561 1 0.0428
0.02 20 0.382 0.676 30 0.641 0.528 0.999 0.0259
0.03 20 0.349 0.628 38 0.666 0.499 0.995 0.0176
0.04 20 0.324 0.589 48 0.681 0.473 0.982 0.0127
0.05 20 0.305 0.557 62 0.693 0.452 0.960 0.0092
0.06 20 0.289 0.530 76 0.699 0.434 0.927 0.0073
0.07 20 0.276 0.508 96 0.706 0.418 0.881 0.0057
0.08 20 0.264 0.488 118 0.710 0.403 0.821 0.0046
(0.1, 0.6) 0.01 28 0.511 0.770 32 0.604 0.483 1 0.0231
0.02 28 0.490 0.737 36 0.631 0.474 1 0.0175
0.03 28 0.477 0.708 40 0.651 0.465 0.998 0.0145
0.04 28 0.467 0.685 46 0.667 0.457 0.991 0.0111
0.05 28 0.461 0.667 54 0.685 0.452 0.978 0.0086
0.06 28 0.458 0.653 62 0.691 0.448 0.959 0.0069
0.07 28 0.457 0.643 70 0.698 0.446 0.934 0.0057
0.08 28 0.458 0.636 78 0.704 0.446 0.903 0.0049
(0.2, 0.7) 0.01 30 0.479 0.750 36 0.608 0.477 1 0.0214
0.02 30 0.447 0.702 44 0.649 0.458 0.999 0.0144
0.03 30 0.426 0.664 54 0.671 0.441 0.991 0.0102
0.04 30 0.411 0.636 66 0.686 0.427 0.974 0.0076
0.05 30 0.401 0.615 78 0.695 0.417 0.947 0.0061
0.06 30 0.395 0.599 92 0.702 0.410 0.912 0.0050
0.07 30 0.391 0.587 106 0.706 0.404 0.868 0.0042
0.08 30 0.388 0.578 122 0.711 0.400 0.816 0.0035
(0.1, 0.5) 0.01 40 0.490 0.751 48 0.614 0.392 1 0.0155
0.02 40 0.493 0.725 54 0.643 0.392 0.999 0.0107
0.03 40 0.498 0.708 60 0.666 0.395 0.993 0.0084
0.04 40 0.504 0.697 66 0.678 0.400 0.981 0.0067
0.05 40 0.514 0.692 72 0.689 0.407 0.965 0.0055
0.06 40 0.525 0.692 76 0.695 0.417 0.945 0.0047
0.07 40 0.538 0.694 80 0.701 0.429 0.923 0.0041
0.08 40 0.552 0.699 80 0.705 0.442 0.899 0.0038
(0.2, 0.6) 0.01 46 0.487 0.742 56 0.624 0.388 1 0.0137
0.02 46 0.475 0.704 68 0.659 0.380 0.996 0.0083
0.03 46 0.471 0.679 82 0.678 0.376 0.981 0.0057
0.04 46 0.472 0.665 94 0.691 0.376 0.956 0.0046
0.05 46 0.477 0.658 106 0.698 0.379 0.925 0.0037
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Table 5 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = 0.001. Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed (Continued)
(τ 21 = 0.001) Traditional design CEP design
(m1,m2) τ 22 Nˆ Performance CEP N
∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
0.06 46 0.484 0.655 114 0.704 0.384 0.890 0.0032
0.07 46 0.493 0.655 120 0.707 0.390 0.851 0.0029
0.08 46 0.502 0.658 126 0.711 0.396 0.810 0.0026
(0.3, 0.7) 0.01 48 0.465 0.724 62 0.630 0.379 1 0.0118
0.02 48 0.440 0.673 82 0.670 0.363 0.990 0.0068
0.03 48 0.429 0.643 104 0.689 0.354 0.963 0.0046
0.04 48 0.426 0.626 124 0.698 0.349 0.924 0.0036
0.05 48 0.425 0.616 144 0.705 0.347 0.879 0.0029
0.06 48 0.427 0.610 158 0.708 0.347 0.829 0.0026
0.07 48 0.431 0.607 172 0.711 0.348 0.776 0.0023
0.08 48 0.435 0.605 182 0.713 0.349 0.718 0.0021
(0.1, 0.4) 0.01 64 0.497 0.735 82 0.635 0.300 0.999 0.0077
0.02 64 0.519 0.720 92 0.667 0.312 0.992 0.0053
0.03 64 0.540 0.717 98 0.680 0.328 0.977 0.0041
0.04 64 0.563 0.722 102 0.691 0.346 0.960 0.0034
0.05 64 0.585 0.730 100 0.696 0.366 0.942 0.0031
0.06 64 0.608 0.741 96 0.700 0.388 0.925 0.0029
0.07 64 0.632 0.754 90 0.703 0.412 0.909 0.0027
0.08 64 0.656 0.768 84 0.706 0.437 0.895 0.0025
(0.2, 0.5) 0.01 78 0.496 0.726 104 0.644 0.297 0.998 0.0057
0.02 78 0.505 0.701 126 0.677 0.302 0.982 0.0036
0.03 78 0.521 0.695 140 0.691 0.313 0.954 0.0027
0.04 78 0.540 0.698 148 0.699 0.327 0.922 0.0023
0.05 78 0.559 0.705 148 0.704 0.342 0.890 0.0021
0.06 78 0.579 0.715 144 0.707 0.358 0.860 0.0019
0.07 78 0.599 0.726 138 0.709 0.375 0.831 0.0018
0.08 78 0.620 0.738 130 0.711 0.393 0.804 0.0018
(0.3, 0.6) 0.01 84 0.474 0.708 120 0.652 0.291 0.997 0.0049
0.02 84 0.477 0.677 156 0.684 0.290 0.970 0.0029
0.03 84 0.489 0.668 180 0.697 0.297 0.928 0.0022
0.04 84 0.504 0.669 194 0.704 0.305 0.882 0.0018
0.05 84 0.520 0.674 198 0.707 0.315 0.838 0.0016
0.06 84 0.536 0.681 198 0.710 0.325 0.795 0.0015
0.07 84 0.551 0.689 194 0.712 0.336 0.753 0.0015
0.08 84 0.566 0.698 188 0.713 0.346 0.712 0.0014
(0.1, 0.3) 0.01 124 0.525 0.718 182 0.671 0.214 0.987 0.0025
0.02 124 0.574 0.730 186 0.688 0.242 0.960 0.0018
0.03 124 0.614 0.749 174 0.695 0.271 0.937 0.0016
0.04 124 0.650 0.768 156 0.699 0.301 0.920 0.0016
0.05 124 0.681 0.787 138 0.702 0.332 0.908 0.0015
0.06 124 0.710 0.805 120 0.704 0.363 0.899 0.0015
0.07 124 0.738 0.822 102 0.704 0.397 0.894 0.0015
0.08 124 0.765 0.840 86 0.705 0.433 0.891 0.0016
(0.2, 0.4) 0.01 164 0.524 0.711 254 0.678 0.210 0.979 0.0017
0.02 164 0.565 0.718 272 0.695 0.233 0.934 0.0012
0.03 164 0.602 0.735 260 0.702 0.258 0.895 0.0010
0.04 164 0.635 0.753 236 0.706 0.283 0.864 0.0010
0.05 164 0.665 0.771 208 0.708 0.309 0.841 0.0010
0.06 164 0.692 0.789 182 0.710 0.335 0.822 0.0010
0.07 164 0.718 0.805 156 0.710 0.362 0.809 0.0010
0.08 164 0.742 0.822 134 0.711 0.389 0.798 0.0010
(0.3, 0.5) 0.01 186 0.509 0.697 314 0.683 0.205 0.971 0.0014
0.02 186 0.545 0.701 348 0.699 0.224 0.909 0.0010
0.03 186 0.580 0.717 336 0.705 0.244 0.857 0.0008
0.04 186 0.610 0.734 310 0.708 0.265 0.815 0.0008
0.05 186 0.638 0.751 280 0.711 0.285 0.780 0.0008
0.06 186 0.663 0.767 250 0.711 0.304 0.751 0.0008
0.07 186 0.686 0.782 222 0.713 0.324 0.726 0.0008
0.08 186 0.707 0.796 194 0.714 0.343 0.704 0.0008
(0.4, 0.6) 0.01 194 0.495 0.684 354 0.686 0.200 0.962 0.0012
0.02 194 0.526 0.685 406 0.702 0.214 0.885 0.0008
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Table 5 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = 0.001. Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed (Continued)
(τ 21 = 0.001) Traditional design CEP design
(m1,m2) τ 22 Nˆ Performance CEP N
∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
0.03 194 0.556 0.698 402 0.707 0.229 0.820 0.0007
0.04 194 0.582 0.712 382 0.710 0.244 0.767 0.0007
0.05 194 0.605 0.726 354 0.712 0.258 0.722 0.0007
0.06 194 0.626 0.739 326 0.713 0.272 0.682 0.0007
0.07 194 0.645 0.751 300 0.714 0.284 0.646 0.0007
0.08 194 0.662 0.763 274 0.715 0.296 0.610 0.0007
(0.1, 0.2) 0.01 398 0.626 0.752 562 0.701 0.145 0.897 0.0005
0.02 398 0.703 0.799 402 0.705 0.190 0.870 0.0005
0.03 398 0.751 0.830 302 0.706 0.230 0.861 0.0005
0.04 398 0.786 0.853 234 0.706 0.268 0.861 0.0005
0.05 398 0.814 0.872 184 0.707 0.305 0.864 0.0005
0.06 398 0.837 0.888 146 0.707 0.343 0.870 0.0005
0.07 398 0.859 0.903 116 0.707 0.384 0.878 0.0005
0.08 398 0.879 0.917 88 0.706 0.429 0.887 0.0006
(0.2, 0.3) 0.01 588 0.623 0.747 874 0.704 0.140 0.864 0.0003
0.02 588 0.697 0.792 630 0.708 0.180 0.813 0.0003
0.03 588 0.743 0.823 470 0.710 0.216 0.791 0.0003
0.04 588 0.778 0.846 362 0.711 0.250 0.782 0.0003
0.05 588 0.806 0.865 284 0.711 0.283 0.779 0.0003
0.06 588 0.829 0.881 224 0.711 0.316 0.780 0.0003
0.07 588 0.849 0.895 176 0.711 0.350 0.785 0.0003
0.08 588 0.868 0.909 138 0.711 0.386 0.793 0.0004
(0.3, 0.4) 0.01 712 0.614 0.739 1126 0.706 0.136 0.841 0.0002
0.02 712 0.684 0.783 830 0.710 0.171 0.774 0.0002
0.03 712 0.730 0.813 628 0.711 0.202 0.740 0.0002
0.04 712 0.764 0.836 488 0.712 0.231 0.720 0.0002
0.05 712 0.791 0.854 388 0.713 0.259 0.708 0.0002
0.06 712 0.814 0.870 310 0.713 0.286 0.701 0.0003
0.07 712 0.834 0.884 250 0.713 0.313 0.697 0.0003
0.08 712 0.852 0.896 200 0.714 0.341 0.697 0.0003
(0.4, 0.5) 0.01 776 0.605 0.732 1298 0.707 0.132 0.823 0.0002
0.02 776 0.672 0.773 984 0.711 0.163 0.742 0.0002
0.03 776 0.715 0.802 762 0.712 0.189 0.698 0.0002
0.04 776 0.747 0.824 608 0.713 0.213 0.668 0.0002
0.05 776 0.773 0.841 494 0.714 0.234 0.646 0.0002
0.06 776 0.794 0.856 406 0.714 0.255 0.629 0.0002
0.07 776 0.813 0.869 338 0.715 0.275 0.614 0.0002
0.08 776 0.829 0.880 282 0.715 0.294 0.602 0.0002
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Table 6 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = 0.08. Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed
(τ 21 = 0.08) Traditional design CEP design
(m1,m2) τ 22 Nˆ Performance CEP N
∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
(0.1, 0.9) 0.001 10 0.127 0.389 70 0.703 0.459 0.913 0.0096
0.01 10 0.097 0.356 88 0.707 0.435 0.861 0.0078
0.02 10 0.083 0.335 102 0.709 0.417 0.815 0.0068
0.03 10 0.075 0.319 118 0.711 0.402 0.774 0.0059
0.04 10 0.069 0.306 132 0.712 0.389 0.734 0.0053
0.05 10 0.064 0.294 148 0.713 0.378 0.693 0.0047
0.06 10 0.060 0.283 166 0.713 0.366 0.650 0.0042
0.07 10 0.056 0.273 186 0.714 0.355 0.602 0.0037
(0.1, 0.8) 0.001 14 0.147 0.399 114 0.710 0.407 0.825 0.0056
0.01 14 0.134 0.387 124 0.710 0.396 0.794 0.0052
0.02 14 0.128 0.377 134 0.711 0.386 0.760 0.0049
0.03 14 0.124 0.368 146 0.712 0.378 0.728 0.0045
0.04 14 0.121 0.360 158 0.713 0.370 0.695 0.0041
0.05 14 0.118 0.353 170 0.713 0.362 0.661 0.0038
0.06 14 0.116 0.346 184 0.714 0.355 0.625 0.0035
0.07 14 0.113 0.339 198 0.715 0.348 0.586 0.0033
(0.1, 0.7) 0.001 20 0.174 0.415 172 0.713 0.355 0.731 0.0035
0.01 20 0.172 0.414 176 0.713 0.353 0.712 0.0035
0.02 20 0.174 0.413 182 0.713 0.350 0.691 0.0033
0.03 20 0.177 0.412 188 0.714 0.348 0.669 0.0032
0.04 20 0.180 0.411 192 0.714 0.346 0.646 0.0031
0.05 20 0.183 0.410 200 0.715 0.344 0.622 0.0030
0.06 20 0.185 0.409 206 0.714 0.342 0.596 0.0028
0.07 20 0.187 0.408 214 0.715 0.340 0.567 0.0027
(0.2, 0.8) 0.001 20 0.264 0.488 118 0.710 0.403 0.821 0.0046
0.01 20 0.247 0.475 128 0.711 0.393 0.789 0.0043
0.02 20 0.233 0.462 138 0.712 0.384 0.755 0.0041
0.03 20 0.223 0.451 150 0.712 0.375 0.723 0.0038
0.04 20 0.215 0.442 162 0.713 0.367 0.690 0.0035
0.05 20 0.208 0.433 174 0.713 0.360 0.656 0.0033
0.06 20 0.201 0.424 188 0.714 0.353 0.620 0.0031
0.07 20 0.195 0.416 202 0.715 0.346 0.580 0.0029
(0.1, 0.6) 0.001 28 0.193 0.426 252 0.715 0.303 0.632 0.0023
0.01 28 0.199 0.431 250 0.715 0.307 0.623 0.0023
0.02 28 0.209 0.437 246 0.715 0.311 0.613 0.0023
0.03 28 0.220 0.443 244 0.715 0.316 0.601 0.0023
0.04 28 0.231 0.449 240 0.715 0.320 0.589 0.0023
0.05 28 0.241 0.456 238 0.715 0.324 0.576 0.0023
0.06 28 0.252 0.463 234 0.715 0.328 0.562 0.0022
0.07 28 0.262 0.469 230 0.715 0.332 0.546 0.0022
(0.2, 0.7) 0.001 30 0.302 0.510 178 0.713 0.352 0.725 0.0028
0.01 30 0.298 0.507 182 0.713 0.350 0.706 0.0027
0.02 30 0.295 0.504 186 0.714 0.348 0.685 0.0027
0.03 30 0.293 0.502 192 0.714 0.346 0.663 0.0026
0.04 30 0.292 0.499 198 0.714 0.344 0.640 0.0025
0.05 30 0.291 0.497 204 0.714 0.342 0.616 0.0024
0.06 30 0.291 0.495 210 0.715 0.340 0.590 0.0024
0.07 30 0.291 0.493 218 0.715 0.338 0.561 0.0023
(0.1, 0.5) 0.001 40 0.213 0.437 364 0.716 0.253 0.531 0.0016
0.01 40 0.226 0.448 350 0.716 0.262 0.530 0.0016
0.02 40 0.244 0.461 334 0.716 0.272 0.529 0.0016
0.03 40 0.264 0.474 318 0.716 0.282 0.528 0.0016
0.04 40 0.283 0.488 300 0.715 0.293 0.527 0.0017
0.05 40 0.303 0.502 284 0.716 0.303 0.526 0.0017
0.06 40 0.323 0.516 266 0.716 0.313 0.525 0.0017
0.07 40 0.342 0.530 248 0.716 0.324 0.523 0.0018
(0.2, 0.6) 0.001 46 0.343 0.536 258 0.715 0.301 0.625 0.0018
0.01 46 0.347 0.539 256 0.715 0.305 0.617 0.0018
0.02 46 0.352 0.543 252 0.715 0.309 0.606 0.0018
0.03 46 0.359 0.547 250 0.715 0.314 0.595 0.0017
0.04 46 0.366 0.552 246 0.715 0.318 0.583 0.0017
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Table 6 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = 0.08. Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed (Continued)
(τ 21 = 0.08) Traditional design CEP design
(m1,m2) τ 22 Nˆ Performance CEP N
∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
0.05 46 0.373 0.556 242 0.715 0.322 0.570 0.0017
0.06 46 0.382 0.562 238 0.715 0.326 0.556 0.0017
0.07 46 0.390 0.567 234 0.716 0.330 0.540 0.0017
(0.3, 0.7) 0.001 48 0.435 0.605 182 0.713 0.349 0.718 0.0021
0.01 48 0.431 0.602 186 0.713 0.347 0.700 0.0020
0.02 48 0.427 0.599 192 0.714 0.345 0.679 0.0020
0.03 48 0.423 0.596 196 0.714 0.343 0.657 0.0020
0.04 48 0.419 0.592 202 0.714 0.342 0.634 0.0019
0.05 48 0.416 0.589 208 0.715 0.340 0.610 0.0019
0.06 48 0.414 0.586 214 0.715 0.338 0.584 0.0018
0.07 48 0.411 0.583 222 0.715 0.336 0.555 0.0017
(0.1, 0.4) 0.001 64 0.258 0.468 532 0.716 0.202 0.428 0.0010
0.01 64 0.281 0.486 494 0.716 0.217 0.435 0.0010
0.02 64 0.308 0.506 452 0.716 0.234 0.444 0.0011
0.03 64 0.336 0.526 412 0.716 0.250 0.454 0.0011
0.04 64 0.363 0.546 374 0.716 0.267 0.464 0.0011
0.05 64 0.391 0.566 338 0.716 0.283 0.475 0.0012
0.06 64 0.418 0.586 302 0.716 0.299 0.487 0.0013
0.07 64 0.446 0.607 268 0.716 0.316 0.501 0.0013
(0.2, 0.5) 0.001 78 0.404 0.577 374 0.716 0.251 0.524 0.0011
0.01 78 0.414 0.585 358 0.716 0.260 0.523 0.0011
0.02 78 0.427 0.594 342 0.716 0.270 0.522 0.0011
0.03 78 0.441 0.604 326 0.716 0.281 0.521 0.0011
0.04 78 0.455 0.615 308 0.716 0.291 0.521 0.0011
0.05 78 0.470 0.625 290 0.716 0.301 0.520 0.0012
0.06 78 0.486 0.637 272 0.716 0.312 0.519 0.0012
0.07 78 0.503 0.649 254 0.716 0.322 0.518 0.0012
(0.3, 0.6) 0.001 84 0.497 0.647 266 0.715 0.299 0.618 0.0012
0.01 84 0.501 0.649 264 0.715 0.303 0.609 0.0012
0.02 84 0.505 0.652 260 0.715 0.307 0.599 0.0012
0.03 84 0.509 0.655 256 0.715 0.311 0.588 0.0012
0.04 84 0.514 0.658 252 0.715 0.316 0.576 0.0012
0.05 84 0.519 0.661 248 0.715 0.320 0.564 0.0012
0.06 84 0.524 0.665 244 0.715 0.324 0.550 0.0012
0.07 84 0.530 0.668 240 0.716 0.328 0.534 0.0012
(0.1, 0.3) 0.001 124 0.339 0.526 808 0.717 0.153 0.323 0.0006
0.01 124 0.376 0.554 708 0.717 0.176 0.341 0.0006
0.02 124 0.414 0.582 612 0.717 0.200 0.361 0.0006
0.03 124 0.450 0.608 530 0.717 0.223 0.382 0.0007
0.04 124 0.483 0.632 458 0.717 0.245 0.404 0.0007
0.05 124 0.515 0.656 394 0.717 0.266 0.428 0.0007
0.06 124 0.546 0.679 338 0.717 0.287 0.452 0.0008
0.07 124 0.578 0.702 286 0.716 0.308 0.480 0.0009
(0.2, 0.4) 0.001 164 0.502 0.647 546 0.717 0.201 0.420 0.0006
0.01 164 0.519 0.659 506 0.716 0.216 0.428 0.0006
0.02 164 0.537 0.672 464 0.717 0.233 0.437 0.0006
0.03 164 0.557 0.686 422 0.717 0.249 0.447 0.0006
0.04 164 0.576 0.700 382 0.716 0.265 0.457 0.0006
0.05 164 0.596 0.715 344 0.716 0.282 0.469 0.0007
0.06 164 0.617 0.730 308 0.716 0.298 0.482 0.0007
0.07 164 0.638 0.745 272 0.716 0.314 0.495 0.0007
(0.3, 0.5) 0.001 186 0.597 0.716 384 0.716 0.249 0.516 0.0006
0.01 186 0.605 0.721 368 0.716 0.258 0.515 0.0006
0.02 186 0.614 0.728 352 0.716 0.269 0.515 0.0006
0.03 186 0.623 0.735 334 0.716 0.279 0.514 0.0006
0.04 186 0.633 0.742 314 0.716 0.289 0.514 0.0006
0.05 186 0.644 0.749 296 0.716 0.299 0.513 0.0007
0.06 186 0.655 0.757 278 0.716 0.310 0.513 0.0007
0.07 186 0.667 0.766 258 0.716 0.320 0.512 0.0007
(0.4, 0.6) 0.001 194 0.662 0.763 274 0.715 0.296 0.610 0.0007
0.01 194 0.664 0.764 270 0.715 0.301 0.602 0.0007
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Table 6 Sample scenarios assuming beta priors p(π1) and p(π2) where τ 21 = 0.08. Hypothesized values of π1 and π2 set equal tom1
andm2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed (Continued)
(τ 21 = 0.08) Traditional design CEP design
(m1,m2) τ 22 Nˆ Performance CEP N
∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
0.02 194 0.667 0.766 266 0.715 0.305 0.592 0.0007
0.03 194 0.669 0.768 262 0.715 0.309 0.581 0.0007
0.04 194 0.672 0.770 258 0.715 0.314 0.569 0.0007
0.05 194 0.675 0.772 254 0.715 0.318 0.557 0.0007
0.06 194 0.679 0.774 250 0.716 0.322 0.543 0.0007
0.07 194 0.682 0.777 244 0.716 0.326 0.528 0.0007
(0.1, 0.2) 0.001 398 0.506 0.648 1346 0.717 0.104 0.218 0.0002
0.01 398 0.563 0.691 978 0.714 0.139 0.247 0.0003
0.02 398 0.606 0.720 814 0.717 0.172 0.286 0.0003
0.03 398 0.642 0.746 660 0.717 0.201 0.319 0.0003
0.04 398 0.673 0.768 542 0.717 0.227 0.352 0.0003
0.05 398 0.700 0.788 450 0.717 0.253 0.386 0.0003
0.06 398 0.726 0.807 372 0.717 0.277 0.422 0.0004
0.07 398 0.751 0.825 304 0.716 0.302 0.460 0.0004
(0.2, 0.3) 0.001 588 0.667 0.765 828 0.717 0.152 0.316 0.0002
0.01 588 0.691 0.783 694 0.714 0.175 0.330 0.0002
0.02 588 0.709 0.794 624 0.717 0.199 0.355 0.0002
0.03 588 0.728 0.808 540 0.717 0.222 0.376 0.0002
0.04 588 0.747 0.821 466 0.717 0.243 0.398 0.0002
0.05 588 0.764 0.834 402 0.717 0.265 0.422 0.0003
0.06 588 0.781 0.846 344 0.717 0.286 0.447 0.0003
0.07 588 0.799 0.858 292 0.716 0.307 0.474 0.0003
(0.3, 0.4) 0.001 712 0.748 0.822 560 0.717 0.200 0.413 0.0002
0.01 712 0.761 0.832 502 0.715 0.215 0.416 0.0002
0.02 712 0.767 0.836 474 0.717 0.231 0.430 0.0002
0.03 712 0.778 0.843 432 0.716 0.248 0.440 0.0002
0.04 712 0.788 0.851 390 0.716 0.264 0.451 0.0002
0.05 712 0.799 0.859 352 0.716 0.280 0.462 0.0002
0.06 712 0.810 0.866 314 0.716 0.296 0.475 0.0002
0.07 712 0.821 0.874 278 0.716 0.312 0.490 0.0002
(0.4, 0.5) 0.001 776 0.797 0.857 394 0.716 0.247 0.508 0.0002
0.01 776 0.803 0.863 368 0.714 0.257 0.503 0.0002
0.02 776 0.806 0.863 360 0.716 0.267 0.507 0.0002
0.03 776 0.811 0.867 342 0.716 0.277 0.507 0.0002
0.04 776 0.816 0.871 322 0.716 0.287 0.507 0.0002
0.05 776 0.822 0.875 302 0.716 0.298 0.506 0.0002
0.06 776 0.827 0.879 284 0.716 0.308 0.506 0.0002
0.07 776 0.834 0.883 264 0.716 0.318 0.506 0.0002
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Table 7 Sample scenarios assuming uniform priors p(π1) and p(π2) where τ 21 = τ 22 . Hypothesized values of π1 and π2 set equal to μ1
and μ2, respectively, under the traditional design. Two-sided α = 0.05 and 1 − β = 0.80 assumed
Traditional design CEP design
(μ1,μ2) τ 21 = τ 22 Nˆ Performance CEP N∗ Performance E(π2 − π1|π2 > π1) P(π2 > π1) Marginal benefit
(0.1, 0.9) 0.001 10 0.638 0.826 10 0.638 0.800 1 0
(0.1, 0.8) or (0.2, 0.9) 0.001 14 0.643 0.824 14 0.643 0.700 1 0
(0.1, 0.7) or (0.3, 0.9) 0.001 20 0.680 0.831 20 0.680 0.600 1 0
(0.2, 0.8) 0.001 20 0.593 0.811 20 0.593 0.600 1 0
0.01 20 0.556 0.775 22 0.615 0.600 1 0.030
(0.1, 0.6) or (0.4, 0.9) 0.001 28 0.633 0.822 28 0.633 0.500 1 0
(0.2, 0.7) or (0.3, 0.8) 0.001 30 0.599 0.812 30 0.599 0.500 1 0
0.01 30 0.554 0.763 36 0.650 0.500 1 0.016
(0.1, 0.5) or (0.5, 0.9) 0.001 40 0.551 0.801 40 0.551 0.400 1 0
(0.2, 0.6) or (0.4, 0.8) 0.001 46 0.553 0.800 46 0.553 0.400 1 0
0.01 46 0.535 0.735 62 0.663 0.400 1 0.008
(0.3, 0.7) 0.001 48 0.555 0.800 48 0.555 0.400 1 0
0.01 48 0.536 0.735 64 0.660 0.400 1 0.008
0.02 48 0.549 0.711 80 0.694 0.407 0.983 0.005
0.03 48 0.575 0.718 82 0.702 0.427 0.945 0.004
(0.1, 0.4) or (0.6, 0.9) 0.001 64 0.523 0.787 68 0.589 0.300 1 0.017
(0.2, 0.5) or (0.5, 0.8) 0.001 78 0.521 0.786 82 0.581 0.300 1 0.015
0.01 78 0.526 0.704 130 0.689 0.303 0.991 0.003
(0.3, 0.6) or (0.4, 0.7) 0.001 84 0.506 0.781 90 0.591 0.300 1 0.014
0.01 84 0.521 0.701 142 0.690 0.303 0.991 0.003
0.02 84 0.566 0.712 150 0.704 0.330 0.925 0.002
0.03 84 0.603 0.731 140 0.709 0.357 0.875 0.002
(0.1, 0.3) or (0.7, 0.9) 0.001 124 0.510 0.764 140 0.600 0.200 1 0.006
(0.2, 0.4) or (0.6, 0.8) 0.001 164 0.512 0.764 184 0.603 0.200 1 0.005
0.01 164 0.566 0.713 292 0.703 0.224 0.911 0.001
(0.3, 0.5) or (0.5, 0.7) 0.001 186 0.504 0.761 210 0.603 0.200 1 0.004
0.01 186 0.562 0.710 336 0.704 0.224 0.911 0.001
0.02 186 0.626 0.745 284 0.709 0.263 0.825 0.001
0.03 186 0.669 0.772 236 0.710 0.295 0.778 0.001
(0.4, 0.6) 0.001 194 0.504 0.761 220 0.607 0.200 1 0.004
0.01 194 0.562 0.709 350 0.704 0.224 0.911 0.001
0.02 194 0.625 0.745 296 0.708 0.263 0.825 0.001
0.03 194 0.668 0.771 248 0.711 0.295 0.778 0.001
0.04 194 0.700 0.792 210 0.712 0.323 0.747 0.001
0.05 194 0.725 0.809 194 0.725 0.349 0.725 0
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